Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

This study examined gene expression in zebrafish embryos exposed to 0 (0.01% DMSO), 16 µM, or 32 µM perfluorobutane sulfonate.

ABSTRACT: This study examined gene expression in zebrafish embryos exposed to 0 (0.01% DMSO), 16 µM, or 32 µM perfluorobutane sulfonate.

PROVIDER: PRJNA471075 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7154530.fastq.gz	Fastqsanger.gz
	SRR7154540.fastq.gz	Fastqsanger.gz
	SRR7154550.fastq.gz	Fastqsanger.gz
	SRR7154531.fastq.gz	Fastqsanger.gz
	SRR7154541.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

This study examined gene expression in zebrafish embryos exposed to 0 (0.01% DMSO), 16 µM, or 32 µM perfluorobutane sulfonate.

Project description:The objective of this study is to compare the toxicity of the emerging replacement surfactant PFBS to the legacy chemical PFOS in the developing pancreas. Because of its chemical properties, it is hypothesized that PFBS would result in fewer or more mild aberrant pancreas phenotypes and ameliorated pancreas gene expression compared to PFOS. Herein, we use transgenic zebrafish models to visualize these processes in vivo throughout the developmental process, and use RNA-Seq to examine major pathways affected by these embryonic exposures.

2019-02-13 | GSE114356 | GEO

Microarray gene expression profiling of zebrafish embryos after 3-hour 0.1% DMSO or 25 µM Beclomethasone treatment

Project description:To uncover the genes regulated by pharmacological activation of the Glucocorticoid Receptor, we performed microarray-based expression profiling of whole zebrafish embryos at 24 and 72 hours post fertilization (hpf) after 3-hour treatment with 25 µM of Beclomethasone, a potent glucocorticoid previously tested in zebrafish or with 0.1 % DMSO as control.

2012-10-30 | GSE41904 | GEO

Next generation sequencing quantitative analysis of C3H10T1/2 cells treated with purmorphamine, DMSO, purmorphamine and Picoberin or DMSO and Picoberin for 24h, 48h, 96h or 7 days

Project description:Purpose: Analysis of the differential gene expression of C3H10T1/2 cells undergoing Hedgehog (Hh) induced osteoblast differentiation compared to unstimulated (DMSO treated) cells and investigation of the differential gene expression caused by Picoberin, a highly potent inhibitor of Hh induced osteoblast differentiation (Comparison of purmorphamin + Picoberin treated C3H10T1/2 cells with purmorphamin + DMSO treated cells) Methods: 80 % confluent C3H10T1/2 cells were treated either with 1.5 µM purmorphamine + DMSO, only DMSO, 1.5 µM purmorphamine + 1 nM Picoberin, 1.5 µM purmorphamine +100 nM Picoberin or DMSO + 100 nM Picoberin for 24h, 48h, 96h or 7 days. Results: Picoberin inhibits osteoblast differentiation

2022-11-30 | GSE197970 | GEO

LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

Project description:LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

| PRJNA579991 | ENA

PolyA-sequencing in IMR-32 cells treated with THZ531 or DMSO

Project description:We performed RNA-seq analsysis of polA transcripts in IMR-32 cells treated with THZ531 for 2 and 6h and DMSO as a control

2019-03-26 | GSE113312 | GEO

Control (DMSO 0.1%; v/v) and 10 µM DRB18 treated A549 lung cancer cells in vitro for 48 hours

Project description:Control (DMSO 0.1%; v/v) and 10 µM DRB18 were used to treated 5 million A549 lung cancer cells in vitro for 48 hours. The untargeted metabolomics analysis was performed on the cell lysates. The main objective of the study was to determine changes in metabolite abundances in lung cancer after treatment with DRB18, an inhibitor of glucose transporter proteins.

2020-11-08 | ST001610 | MetabolomicsWorkbench

LX-2 cells pretreated with CM272 (400nM) or vehicle (0.01%DMSO)

Project description:LX-2 cells were pretreated with CM272 (400nM) or vehicle (0.01%DMSO) for 24 hours followed by incubation of TGFβ1 (5ng/ml) for another 24 hours.

2019-10-29 | GSE139504 | GEO

Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset Pompe disease patient fibroblasts

Project description:human Pompe Disease (c.-32-13T>G) fibroblasts were exposed to 10 µM Deferoxamine (DFX) or 0.1% DMSO (control condition), for three days.

2021-01-19 | GSE155637 | GEO

Nascent RNA sequencing in IMR-32 cells treated with THZ531 or DMSO

Project description:We performed RNA-seq analsysis of nascent transcripts obtained by 4sU labeling in IMR-32 cells treated with THZ531 for 30min and 2h and DMSO as a control

2019-03-26 | GSE113313 | GEO

Gene expression profiling of human neuroblastoma cell line SMS-KCNR treated with DMSO, simvastatin at 5 µM or simvastatin at 5 µM plus mevalonate at 2 mM for 30 hours

Project description:Gene expression profiling of human neuroblastoma cell line SMS-KCNR treated with DMSO, simvastatin at 5 µM or simvastatin at 5 µM plus mevalonate at 2 mM for 30 hours

| PRJNA891335 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data